Effect of ß-interferon and methylprednisolone in COVID-19

The assessment of therapeutic effect of ß-interferon and Methylprednisolone in patients with COVID- 19: A quasi-experimental, double-blind, placebo-controlled study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200825048514N1

Enrollment

Registered

2020-10-10

Start date

2020-05-04

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid- 19. Covid- 19

Interventions

Intervention 1: Intervention group: On the first day of hospitalization according to the national treatment protocol, Keltra received 400 mg daily (morning and night), naproxen 250 mg (morning and nig

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age 18- 80 years Covid-19 infection based on high-resolution computed tomography findings Progressive and severe hypoxia based on blood oxygen saturation level less than 88% with a reservoir bag mask and flow of 15 liters Exacerbation of lymphopenia during hospitalization

Exclusion criteria

Exclusion criteria: Cardiovascular patients Grade 3 and more liver cirrhosis Autoimmune diseases Severe depression and psychosis Organ transplantation Kidney failure Pregnancy

Design outcomes

Primary

Measure	Time frame
Body temperature. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Vital Sign Monitoring Device.;Blood pressure. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Blood pressure cuff monitoring vital signs.;Respiration rate. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Vital Sign Monitoring Device.;O2 saturation. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Pulse oximeter.;White blood cells. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Measurements are performed using an automatic blood cell counting device.;Neutrophil. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Measurements are performed using an automatic blood cell counting device.;Lymphocytes. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Measurements are performed using an automatic blood cell counting device.;Platelet. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Measurements are performed using an automatic blood cell counting device.;Erythrocyte Sedimentation Rate. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Measurement is done by centrifugation.;C-Reactive Protein. Timepoint: At the beginning of the study (before	—

Measure

Time frame

Body temperature. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Vital Sign Monitoring Device.;Blood pressure. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Blood pressure cuff monitoring vital signs.;Respiration rate. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Vital Sign Monitoring Device.;O2 saturation. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Pulse oximeter.;White blood cells. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Measurements are performed using an automatic blood cell counting device.;Neutrophil. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Measurements are performed using an automatic blood cell counting device.;Lymphocytes. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Measurements are performed using an automatic blood cell counting device.;Platelet. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Measurements are performed using an automatic blood cell counting device.;Erythrocyte Sedimentation Rate. Timepoint: At the beginning of the study (before the intervention) and during the days of hospitalization on a daily basis. Method of measurement: Measurement is done by centrifugation.;C-Reactive Protein. Timepoint: At the beginning of the study (before

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh sadat Aghaei meybodi

Yazd University of Medical Sciences

dr.meybodi@gmail.com+98 35 3822 4000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026